Dorzagliatin and 1st Phase Insulin and Beta-cell Glucose Sensitivity in IGT and NGT
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Dorzagliatin, a novel dual allosteric activator of glucokinase. reduces blood glucose by
increasing insulin secretion by enhancing sensitivity of beta cells to glucose. In this
placebo controlled cross over study, we examined the effects of dorzagliatin in people with
impaired glucose tolerance and normal glucose tolerance.